Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 27, 2009

La Jolla Institute to Test IVT’s Delivery Platform with Infectious Disease Candidates

  • ImmunoVaccine Technologies (IVT) signed an agreement with the La Jolla Institute for Allergy & Immunology to test the application of its DepoVax™ vaccine delivery system for influenza and arenavirus vaccines.

    The institute’s epitope-based vaccines are in preclinical research. The goal is that using DepoVax, only one vaccine dose will be required for protective immunity and that a strong cellular and humoral response is achieved.

    DepoVax uses liposomes to encapsulate a target antigen and adjuvant. The vaccine formulation also relies on a hydrophobic oil carrier. The result is a depot effect that enhances vaccine induced cell-mediated and humoral immunity, according to IVT.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »